Sudan and South Sudan Pharmaceuticals and Healthcare Report Q2 2015

63 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Access to healthcare in Sudan and South Sudan is poor and drug shortages are commonplace.
The state is also heavily reliant on importing its medicines, though over the long-term we believe this
reliance will decrease as the government is committed to developing domestic pharmaceutical production.
Headline Expenditure Projections
? Pharmaceuticals: SDG2.06bn (USD353mn) in 2014 to SDG2.37bn (USD387mn) in 2015; +15.0% in
local currency terms and +9.8% in US dollar terms. Forecast revised upwards from Q115.
? Healthcare: SDG20.31bn (USD3.48bn) in 2014 to SDG22.85bn (USD3.73bn) in 2015; +12.5% in local
currency terms and +7.4% in US dollar terms. Forecast revised upwards from Q115.

Table of Contents

BMI Industry View 7
SWOT 9
Political 10
Economic 11
Operational Risk 12
Industry Forecast 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sudan 2011-2019) 19
Healthcare Market Forecast 20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2011-2019) 22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2011-2019) 23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2011-2019) 23
Macroeconomic Forecasts 24
Economic Analysis 24
Table: Economic Activity (Sudan 2010-2019) 27
Industry Risk Reward Indicies 28
Middle East And Africa Risk/Reward Index 28
Sudan Risk/Reward Index 36
Rewards 36
Risks 36
Market Overview 38
Industry Trends And Developments 40
Regulatory Development 44
Regulatory Regime 44
Demographic Forecast 47
Sudan Demographic Forecast 47
Table: Population Headline Indicators (Sudan 1990-2025) 48
Table: Key Population Ratios (Sudan 1990-2025) 48
Table: Urban/Rural Population & Life Expectancy (Sudan 1990-2025) 49
Table: Population By Age Group (Sudan 1990-2025) 49
Table: Population By Age Group % (Sudan 1990-2025) 50
South Sudan Demographic Forecast 52
Table: Population Headline Indicators (South Sudan 1990-2025) 53
Table: Key Population Ratios (South Sudan 1990-2025) 53
Table: Urban/Rural Population & Life Expectancy (South Sudan 1990-2025) 54
Table: Population By Age Group (South Sudan 1990-2025) 54
Table: Population By Age Group % (South Sudan 1990-2025) 55
Glossary 57
Methodology 59
Pharmaceutical Expenditure Forecast Model 59
Healthcare Expenditure Forecast Model 59
Notes On Methodology 60
Risk/Reward Index Methodology 61
Index Overview 62
Table: Pharmaceutical Risk/Reward Index Indicators 62
Indicator Weightings 63

List of Tables

Table: Pharmaceutical Sales, Historical Data And Forecasts (Sudan 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2011-2019)
Table: Economic Activity (Sudan 2010-2019)
Table: Population Headline Indicators (Sudan 1990-2025)
Table: Key Population Ratios (Sudan 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Sudan 1990-2025)
Table: Population By Age Group (Sudan 1990-2025)
Table: Population By Age Group % (Sudan 1990-2025)
Table: Population Headline Indicators (South Sudan 1990-2025)
Table: Key Population Ratios (South Sudan 1990-2025)
Table: Urban/Rural Population & Life Expectancy (South Sudan 1990-2025)
Table: Population By Age Group (South Sudan 1990-2025)
Table: Population By Age Group % (South Sudan 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Sudan and South Sudan Pharmaceuticals and Healthcare Report Q3 2015BMI View: Due to the lack of production capacity among domestic companies, the majority of pharmaceuticals in Sudan and South Sudan will remain sourced from abroad. Over the long-term, domestic manufacturers will increase their market share, with the government placing an increasing emphasis on achieving self-sufficiency in terms of pharmaceutical production. Headline Expenditure Projections ? Pharmaceuticals: SDG2.35bn (USD402mn) in 2014 to SDG2.65bn (USD433mn) in 2015; +12.9% […]
  • China Pharmaceuticals and Healthcare Report Q2 2015BMI View: Pharmaceutical sales in China will continue to grow robustly - boosted by the improvement in healthcare access, liberalisation of the industry as well as an epidemiological transition towards chronic diseases. This will present strong revenue earning opportunities for both domestic and multinational pharmaceutical companies. However, downside risks to this upbeat outlook remain as the government will face pressures to contain medicine costs. Headline Expenditure […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Iran Pharmaceuticals and Healthcare Report Q4 2015BMI View: Iran's pharmaceutical market holds significant potential for innovative drugmakers, particularly with the easing of sanctions. This potential is unlikely to be realised in the near term, however, as the government operates in favour of the well developed domestic industry. Headline Expenditure Projections ? Pharmaceuticals: IRR60.70tn (USD2.35bn) in 2014 to IRR69.55trn (USD1.93bn) in 2015; +14.6% in local currency terms and -17.8% in US dollar terms. Forecast upgraded […]
  • Sudan Pharmaceuticals and Healthcare Report Q3 2014BMI View: Overall pharmaceutical sales in Sudan and South Sudan are to see double-digit growth, albeit from a low base. In addition, we highlight that high inflation, volatile currency exchange rates and civil unrests are some of the key risks that will continue to limit pharmaceutical growth potential in Sudan and South Sudan. Headline Expenditure Projections ? Pharmaceuticals: SDG2.60bn (USD560mn) in 2013 to SDG3.29bn (USD540mn) in 2014; +26.4% in local currency terms and -3.1% in […]